

Abstract Plain Language Summaries at Scientific Congresses



What are abstract plain language summaries (APLS)?

APLS use simple visuals, plain language and consistent terminology to describe the research presented at scientific congresses, or meetings. Each APLS represents a small piece of the complete body of data available on the drug and disease area today.

APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe. The results *might be different from the outcome of other* studies that researchers have presented in the past. It's important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.

WHO ARE APLS FOR?

APLS can help research findings be accessible and understandable to anyone seeking this information. Audiences may include but are not limited to patients, caregivers, and healthcare professionals.

WHAT INFORMATION DO **APLS INCLUDE?**

HOW ARE APLS USED?

APLS can help people better understand the research data in presentations at scientific congresses.

WHY DOES PFIZER **DEVELOP APLS?**

Research findings often use terms that can be too complex for many non-scientists to understand. APLS provide recent research results in a clear way for non-scientists.

Presentations will go live on the date marked below.

APLS summarize the original content of a scientific abstract. They describe the main aims and findings of a research study in an easy-to-understand format by following health literacy best practices.


> **European Hematology Association** (EHA) 2022 Hybrid Congress Vienna, Austria | June 9-12, 2022


PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES AND ACCOMPANYING SCIENTIFIC PRESENTATIONS AT EHA 2022

Multiple Myeloma

A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Initial safety results for MagnetisMM-3 Live Friday, June 10

Updated results from the ongoing phase 1 study of elranatamab, a BCMA targeted T-cell redirecting immunotherapy, for patients with relapsed or refactory





VIEW PLAIN LANGUAGE SUMMARY \rightarrow

VIEW PRESENTATION \rightarrow

multiple myeloma

Live Friday, June 10

VIEW PLAIN LANGUAGE SUMMARY \rightarrow

VIEW PRESENTATION \rightarrow

Chronic Myeloid Leukemia

Efficacy and safety of bosutinib in later-line patients with chronic myeloid leukemia: A sub-analysis from the phase 4 BYOND trial

Live Friday, June 10

Bosutinib in newly diagnosed chronic myeloid leukemia: Gastrointestinal, liver, effusion and renal safety characterization in the BFORE trial

Live Friday, June 10

Acute Myeloid Leukemia

A phase 4 study of fractionated gemtuzumab ozogamicin on QT interval and safety in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Live Friday, June 10

VIEW PLAIN LANGUAGE SUMMARY \rightarrow

VIEW PRESENTATION \rightarrow

VIEW PLAIN LANGUAGE SUMMARY →

VIEW PRESENTATION \rightarrow

VIEW PLAIN LANGUAGE SUMMARY \rightarrow

VIEW PRESENTATION \rightarrow



©2022